Nautilus™ ECMO Oxygenator
Circular flow-path design improves long-term gas transfer.1 Designed for durability1 and long-term performance, Nautilus™* ECMO Oxygenator is ready to be incorporated into your current ECMO circuit.
Overview
Changing the Shape of ECMO
View the animation to see how the Nautilus™ ECMO Oxygenator was designed specifically for extracorporeal membrane oxygenation (ECMO), featuring:
- Long-term† ECMO Indication
- PMP Fiber
- Balance™ Biosurface
- Circular Flow-path Design
DEVICE FEATURES
DESIGNED FOR ECMO
CIRCULAR FLOW-PATH TECHNOLOGY
The Nautilus™ ECMO Oxygenator has a transverse flow-path with a circular profile. Transverse flow minimises surface contact area while achieving a low blood-side pressure drop. The circular profile eliminates corners where low flow and stasis are known to occur.
Circular Shape
Eliminates corners, areas known for clotting
Guided Inlet
Reduces velocity changes at the inlet where low flow and stasis may occur
Filling Vanes
Aid in even filling and even flow distribution across the membrane
PERFORMANCE DATA
Designed for durability1 and long-term performance.
BLOOD PATH PRESSURE DROP
HEAT EXCHANGE PERFORMANCE FACTOR
OXYGEN TRANSFER
CARBON DIOXIDE TRANSFER
Bench data; may not be indicative of clinical performance.
ORDERING INFORMATION
Contact your local Medtronic representative for availability in your country.
| Code |
|
|---|---|
| 48145E |
Nautilus™ ECMO Oxygenator with Balance™ Biosurface |
| 48160 |
Nautilus™ Oxygenator Holder |
Additional resources
Medtronic Academy
Find additional feature information along with a variety of educational resources and tools.
Visit Medtronic Academy
*
Third party brands are trademarks of their respective owners.
†
Indicated in Europe for use up to 14 days and in the U.S. for use up to 48 hours.
Reference
1
Data on file at MC3. These tests may not be indicative of clinical performance.
Nautilus™* ECMO Oxygenator is manufactured by MC3, Inc., and exclusively distributed by Medtronic.
Balance™ is a trademark of Medtronic. Technology licensed under agreement from BioInteractions, Limited, United Kingdom.